Phase I Oncology & Cellular Immunotherapy Research Fellowship
Carolina BioOncology Institute PLLC (CBI), founded in 2005 by John Powderly, MD, is a community based independent clinic, located in Huntersville, NC (10 miles north of Charlotte, near Lake Norman). The mission of the clinic is to provide access to early phase immunotherapy clinical trials. 100% Of referrals are stage IV metastatic solid tumor cancer patients seeking access to immunotherapy trials. Dr. Powderly is Adjunct Assistant Professor Medicine at Duke and UNC.
The clinic has treated >3,500 oncology patients and has opened >90 early phase BioPharma sponsored trials focused on immunotherapy, and performs 2,000 research visits/year. BioCytics Inc is a Human Applications Lab incubated at CBI, and is currently developing personalized autologous T cell immunotherapy (with multiple biopharma and biotech partnerships). CBI and BioCytics are the only independent Phase I Cancer Clinic and Human Applications Lab in the US.
Currently accepting Medical Oncology applicants for a Phase I Oncology & Cellular Immunotherapy Research Fellowship from July 1, 2018 - June 30, 2020. Candidates must be oncology board eligible or board certified. Prefer combined MD/PhD candidates, or MD with strong clinical research or translational research background in cellular immunotherapy. Most importantly, candidates must have outstanding interpersonal skills, entrepreneurial spirit, love of patient care, and clinical research. Candidates must submit their CVs by October 31rst, for November/December Interviews, and two Fellows will be chosen by Jan 2018, to start in July 2018.
Fellows will learn principals of oncology drug development, FDA Regulations for Sponsor GMP & Investigator Clinical Site GCP, FACT Guidelines for Immune Effector Cells & Cell Processing principals. Fellows will train in all aspects of oncology Phase I interdisciplinary clinical management, leukapheresis, cell therapy processing, ex-vivo culture, QA/QC, immune safety monitoring. Fellows will become sub-investigators on multiple phase I studies, and have 25% protected time to co-develop multiple INDs for novel Immune Cell therapy. They will learn protocol development, contracts, budgets, operational, regulatory, and business management aspects of phase I development & cell therapy. Fellows will attend weekly didactics, work closely with multiple PhD immunologists, biopharma sponsors, and have limited 1:6 weekend on-call, with oncology hospital privileges (anticipate minimal hospital duties). Graduates of this fellowship will have gained experience to manage Phase I Oncology Programs, Cell Therapy Programs, and/or BioPharma Drug Development Programs.
Interested candidates, submit CV and cover letter to Dr. John Powderly: email@example.com